ARTICLE | Deals
The deal, among the biggest in years for a priority review voucher, comes weeks after a continuing resolution kept the program alive until December
By Paul Bonanos, Director of Biopharma Intelligence
November 6, 2024 12:38 AM UTC
The $150 million price tag in Acadia’s sale of a priority review voucher is among the largest in years, suggesting doubts about the reauthorization of FDA’s pediatric voucher program are driving up the vouchers’ cost.
For years, the price of the transferable vouchers had hovered around $100 million. One other transaction in the past few months, an August sale of a voucher by Ipsen Group (Euronext:IPN; Pink:IPSEY), came in substantially higher at $158 million…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654099/with-doubts-about-voucher-program-extension-acadia-strikes-150m-sale